Taltz (Ixekizumab) for Psoriasis

Overview
Taltz is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with active psoriatic arthritis or moderate to severe plaque psoriasis in cases where systemic therapy or phototherapy are recommended. Taltz is also known by its drug name, ixekizumab.

Taltz is a biologic drug, specifically a human monoclonal antibody. Taltz is believed to work by binding to a protein, interleukin-17A, that promotes inflammation.

How do I take it?
Taltz is administered by subcutaneous injection every four weeks, after the initial loading doses.

Taltz is available in an auto-injector or a prefilled syringe.

Side effects
The FDA-approved label for Taltz lists common side effects including injection site reactions, upper respiratory tract infections, nausea, and ringworm.

Rare but serious side effects listed for Taltz include serious infections such as tuberculosis, hypersensitivity reactions, and inflammatory bowel disease.

For more details about this treatment, visit:

Taltz — Eli Lilly and Company
www.taltz.com